A novel model of metastatic conjunctival melanoma in immune-competent mice

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 10, 2015, Pages 5965-5973

  Schlereth, Simona L ^a   Iden, Sandra ^a   Mescher, Melina ^a   Ksander, Bruce R ^b   Bosch, Jacobus J ^c   Cursiefen, Claus ^a   Heindl, Ludwig M ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

(lymph) angiogenesis; B16F10; Conjunctival melanoma; Hepatocyte growth factor; Metastasis; Mouse model; Ocular melanoma

Indexed keywords

CELL PROTEIN; CYCLIN DEPENDENT KINASE 4; DOPACHROME TAUTOMERASE; KI 67 ANTIGEN; LYMPHATIC VESSEL ENDOTHELIAL HYALURONAN RECEPTOR; PROTEIN S 100; SCATTER FACTOR; UNCLASSIFIED DRUG; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONJUNCTIVAL MELANOMA; CONTROLLED STUDY; EYE MELANOMA; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LYMPHANGIOGENESIS; LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; ANIMAL; C57BL MOUSE; CONJUNCTIVA TUMOR; DISEASE MODEL; IMMUNOCOMPETENCE; LYMPH NODE METASTASIS; MALE; MELANOMA; METABOLISM; PATHOLOGY; PROGNOSIS; SECONDARY; TUMOR CELL CULTURE;

ANIMALS; BIOMARKERS, TUMOR; CELL PROLIFERATION; CONJUNCTIVAL NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MALE; MELANOMA; MICE; MICE, INBRED C57BL; PROGNOSIS; TUMOR CELLS, CULTURED;

EID: 84942054319     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.15-17290     Document Type: Article

References (45)

1. Tuomaala S, Eskelin S, Tarkkanen A, Kivela T. Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites. Invest Ophthalmol Vis Sci. 2002;43:3399–3408.
2. Shildkrot Y, Wilson MW. Conjunctival melanoma: pitfalls and dilemmas in management. Curr Opin Ophthalmol. 2010;21: 380–386.
3. Shields CL, Shields JA, Gunduz K, et al. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol. 2000;118:1497–1507.
4. Seregard S. Conjunctival melanoma. Surv Ophthalmol. 1998; 42:321–350.
5. Tuomaala S, Toivonen P, Al-Jamal R, Kivela T. Prognostic significance of histopathology of primary conjunctival melanoma in Caucasians. Curr Eye Res. 2007;32:939–952.
6. Seregard S, Kock E. Conjunctival malignant melanoma in Sweden 1969-91. Acta Ophthalmol (Copenh). 1992;70:289–296.
7. Heindl LM, Hofmann-Rummelt C, Adler W, et al. Tumorassociated lymphangiogenesis in the development of conjunctival squamous cell carcinoma. Ophthalmology. 2010;117: 649–658.
8. Heindl LM, Hofmann-Rummelt C, Adler W, et al. Prognostic significance of tumor-associated lymphangiogenesis in malignant melanomas of the conjunctiva. Ophthalmology. 2011; 118:2351–2360.
9. Heindl LM, Hofmann-Rummelt C, Adler W, et al. Tumorassociated lymphangiogenesis in the development of conjunctival melanoma. Invest Ophthalmol Vis Sci. 2011;52:7074–7083.
10. Zimmermann P, Dietrich T, Bock F, et al. Tumour-associated lymphangiogenesis in conjunctival malignant melanoma. Br J Ophthalmol. 2009;93:1529–1534.
11. Feng X, Degese MS, Iglesias-Bartolome R, et al. Hippoindependent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell. 2014;25:831–845.
12. Shoushtari AN, Carvajal RD. GNAQ and GNA11 mutations in uveal melanoma. Melanoma Res. 2014;24:525–534.
13. Triay E, Bergman L, Nilsson B, All-Ericsson C, Seregard S. Time trends in the incidence of conjunctival melanoma in Sweden. Br J Ophthalmol. 2009;93:1524–1528.
14. Inskip PD, Devesa SS, Fraumeni JF Jr. Trends in the incidence of ocular melanoma in the United States, 1974-1998. Cancer Causes Control. 2003;14:251–257.
15. Yu GP, Hu DN, McCormick S, Finger PT. Conjunctival melanoma: is it increasing in the United States? Am J Ophthalmol. 2003;135:800–806.
16. Tormo D, Ferrer A, Gaffal E, et al. Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation. Am J Pathol. 2006;169:665–672.
17. Landsberg J, Kohlmeyer J, Renn M, et al. Melanomas resist Tcell therapy through inflammation-induced reversible dedifferentiation. Nature. 2012;490:412–416.
18. Schlereth SL, Neuser B, Caramoy A, et al. Enrichment of lymphatic vessel endothelial hyaluronan receptor 1(LYVE-1)- positive macrophages around blood vessels in the normal human sclera. Invest Ophthalmol Vis Sci. 2014;55:865–872.
19. Schlereth S, Lee HS, Khandelwal P, Saban DR. Blocking CCR7 at the ocular surface impairs the pathogenic contribution of dendritic cells in allergic conjunctivitis. Am J Pathol. 2012; 180:2351–2360.
20. Schwartzkopff J, Schlereth SL, Berger M, et al. NK cell depletion delays corneal allograft rejection in baby rats. Mol Vis. 2010;16:1928–1935.
21. Schroedl F, Kaser-Eichberger A, Schlereth SL, et al. Consensus statement on the immunohistochemical detection of ocular lymphatic vessels. Invest Ophthalmol Vis Sci. 2014;55:6440–6442.
22. Heindl LM, Hofmann TN, Adler W, et al. Intraocular tumorassociated lymphangiogenesis a novel prognostic factor for ciliary body melanomas with extraocular extension? Ophthalmology. 2010;117:334–342.
23. Heindl LM, Hofmann TN, Knorr HL, et al. Intraocular lymphangiogenesis in malignant melanomas of the ciliary body with extraocular extension. Invest Ophthalmol Vis Sci. 2009;50:1988–1995.
24. Heindl LM, Hofmann TN, Schrodl F, Holbach LM, Kruse FE, Cursiefen C. Intraocular lymphatics in ciliary body melanomas with extraocular extension: functional for lymphatic spread? Arch Ophthalmol. 2010;128:1001–1008.
25. Heindl LM, Schrodl F, Lutjen-Drecoll E, Cursiefen C. Ciliary body lymphangiogenesis. Ophthalmology. 2013;120:e41–e42.
26. Koch KR, Refaian N, Hos D, et al. Autocrine impact of VEGF-A on uveal melanoma cells. Invest Ophthalmol Vis Sci. 2014;55: 2697–2704.
27. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004;113:1040–1050.
28. Bock F, Maruyama K, Regenfuss B, et al. Novel anti(lymph)- angiogenic treatment strategies for corneal and ocular surface diseases. Prog Retin Eye Res. 2013;34:89–124.
29. Hos D, Schlereth SL, Bock F, Heindl LM, Cursiefen C. Antilymphangiogenic therapy to promote transplant survival and to reduce cancer metastasis: What can we learn from the eye? Semin Cell Devel Biol. 2015;38:117–130.
30. de Waard NE, Cao J, McGuire SP, et al. A murine model for metastatic conjunctival melanoma. Invest Ophthalmol Vis Sci. 2015;.
31. Lattier JM, Yang H, Crawford S, Grossniklaus HE. Host pigment epithelium-derived factor (PEDF) prevents progression of liver metastasis in a mouse model of uveal melanoma. Clin Exp Metastasis. 2013;30:969–976.
32. Dithmar S, Adams AW, Rusciano D, Grossniklaus HE. Metastatic uveal melanoma. Development of neoadjuvant treatment in animal experiments [in German]. Ophthalmologe. 2001;98: 761–765.
33. Dithmar S, Albert DM, Grossniklaus HE. Animal models of uveal melanoma. Melanoma Res. 2000;10:195–211.
34. Cruz-Munoz W, Man S, Xu P, Kerbel RS. Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. Cancer Res. 2008;68:4500–4505.
35. Munoz R, Man S, Shaked Y, et al. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 2006;66:3386–3391.
36. Francia G, Emmenegger U, Lee CR, et al. Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using betahuman choriogonadotropin secreting tumor cell lines. Mol Cancer Ther. 2008;7:3452–3459.
37. Kubota T. Metastatic models of human cancer xenografted in the nude mouse: the importance of orthotopic transplantation. J Cell Biochem. 1994;56:4–8.
38. Furukawa T, Kubota T, Watanabe M, Kitajima M, Hoffman RM. A novel ‘‘patient-like’’ treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice. Cancer Res. 1993;53:3070–3072.
39. Kiguchi K, Kubota T, Aoki D, et al. A patient-like orthotopic implantation nude mouse model of highly metastatic human ovarian cancer. Clin Exp Metastasis. 1998;16:751–756.
40. Price JE, Zhang RD. Studies of human breast cancer metastasis using nude mice. Cancer Metastasis Rev. 1990;8:285–297.
41. Brandner JM, Haass NK. Melanoma’s connections to the tumour microenvironment. Pathology. 2013;45:443–452.
42. Schlereth SL, Refaian N, Iden S, Cursiefen C, Heindl LM. Impact of the prolymphangiogenic crosstalk in the tumor microenvironment on lymphatic cancer metastasis. BioMed Res Int. 2014;2014:639058.
43. Goubran HA, Kotb RR, Stakiw J, Emara ME, Burnouf T. Regulation of tumor growth and metastasis: the role of tumor microenvironment. Cancer Growth Metastasis. 2014;7:9–18.
44. Weiss L. Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metastasis Rev. 2000;19:I–XI, 193–383.
45. Fidler IJ. Models for spontaneous metastasis. Cancer Res. 2006;66:9787.